FDA Granted Minor Use Status to Canine Cancer Drug
The FDA designated CannEpil, a CBD and THC oral solution, for treating bone cancer pain in dogs.
Updated on Oct. 5, 2026 in Cancer
Live Poll
Should the FDA accelerate approval processes for drugs treating uncommon health conditions in pets?
The FDA Center for Veterinary Medicine has classified CannEpil as a minor use drug under the MUMS program. This designation allows the developers to pursue conditional approval for treating bone cancer pain in canines.
Why it matters
The MUMS program facilitates the development of new animal drugs for uncommon conditions affecting small animal populations. This status provides a pathway for companies to bring niche treatments to market by meeting safety and manufacturing standards before gathering full effectiveness data.
CannEpil is an investigational oral solution formulated with both CBD and THC. The current designation remains in effect until the developers secure final approval of their New Animal Drug Application.
The players
Endovia
Endovia is a pharmaceutical company working alongside Lupvindol to develop and bring the canine pain treatment to the U.S. market.
Lupvindol
Lupvindol is a developer collaborating on the regulatory process and manufacturing supply chain for CannEpil.
FDA Center for Veterinary Medicine
This federal agency is responsible for regulating animal drugs and manages the MUMS program for rare or minor use conditions.
The details
Companies Endovia and Lupvindol are currently establishing a U.S.-based manufacturing supply chain to support the drug. They must demonstrate satisfaction of FDA safety standards to maintain eligibility for the conditional approval pathway.
Timeline
October 5, 2026: The FDA officially announced the minor use determination for CannEpil.
November 19, 2026: Endovia and Lupvindol are scheduled to meet with the FDA for a pre-submission conference.
2027: The companies project a potential commercial veterinary launch of the product.
Health Landscape
The designation for CannEpil follows the established regulatory pattern set by the MUMS program to incentivize the creation of niche veterinary medicines. This program mirrors human orphan drug laws by lowering the barrier to entry for treatments targeting uncommon animal health conditions.
The drug's development offers a potential future treatment option for owners of dogs suffering from bone cancer pain. Conditional approval will eventually allow for commercial availability of the product before the completion of full effectiveness trials.
The takeaway
The MUMS designation highlights how federal policy is being utilized to address pain management for pets with uncommon health conditions. Owners of affected dogs may see this specialized treatment reach the market as early as 2027 following the completion of required safety standards.
What happens next
Endovia and Lupvindol are scheduled to conduct a pre-submission conference with the FDA on November 19, 2026.
Further reading
For more information on the evolving landscape of veterinary oncology, visit the Cancer section.
Live Poll
Should the FDA accelerate approval processes for drugs treating uncommon health conditions in pets?
